Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/57779
Type
ArticleCopyright
Open access
Sustainable Development Goals
03 Saúde e Bem-EstarCollections
- INI - Artigos de Periódicos [3646]
Metadata
Show full item record
RAPID DEVELOPMENT OF AN INTEGRATED NETWORK INFRASTRUCTURE TO CONDUCT PHASE 3 COVID-19 VACCINE TRIALS
Author
Lora, Alfredo J. Mena
Long, Jessica E.
Huang, Yunda
Baden, Lindsey R.
Sahly, Hana M. El
Follmann, Dean
Goepfert, Paul
Gray, Glenda
Grinsztejn, Beatriz
Kotloff, Karen
Rouphael, Nadine
Sobieszczyk, Magdelena
Walsh, Stephen R.
Andriesen, Jessica
Shah, Karan A.
Yuanyuan, Zhang
Gilbert, Peter
Janes, Holly
Gay, Cynthia L.
Falsey, Ann R.
Tripp, Rebecca L.
Gorman, Richard L.
Tong, Tina
Marovich, Mary
Neuzil, Kathleen
Corey, Lawrence
Kublin, James G.
Long, Jessica E.
Huang, Yunda
Baden, Lindsey R.
Sahly, Hana M. El
Follmann, Dean
Goepfert, Paul
Gray, Glenda
Grinsztejn, Beatriz
Kotloff, Karen
Rouphael, Nadine
Sobieszczyk, Magdelena
Walsh, Stephen R.
Andriesen, Jessica
Shah, Karan A.
Yuanyuan, Zhang
Gilbert, Peter
Janes, Holly
Gay, Cynthia L.
Falsey, Ann R.
Tripp, Rebecca L.
Gorman, Richard L.
Tong, Tina
Marovich, Mary
Neuzil, Kathleen
Corey, Lawrence
Kublin, James G.
Affilliation
University of Illinois at Chicago. Division of Infectious Diseases, Department of Medicine. Chicago, USA.
University of Washington, Seattle. Department of Medicine. Washington, DC, USA.
Fred Hutchinson Cancer Center. Vaccine and Infectious Disease Division. Seattle, Washington, USA / Fred Hutchinson Cancer Center. Statistical Center for HIV/AIDS Research & Prevention. Washington, DC, USA.
Brigham and Women's Hospital. Division of Infectious Diseases, Boston, Massachusetts, USA.
Baylor College of Medicine, Houston. Infectious Diseases Section, Department of Medicine. Texas, USA / Baylor College of Medicine. Department of Molecular Virology and Microbiology. Houston, Texas, USA.
National Institutes of Health. National Institute of Allergy and Infectious Diseases. Biostatistics Research Branch. Bethesda, Maryland, USA.
University of Alabama at Birmingham. Division of Infectious Diseases, Department of Medicine. Alabama, USA.
University of the Witwatersrand. Faculty of Health Sciences. Perinatal HIV Research Unit. Johannesburg, South Africa / South African Medical Research Council. Cape Town, South Africa.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. HIV/STI Clinical Research Laboratory. Rio de Janeiro, RJ, Brazil.
University of Maryland School of Medicine. Department of Pediatrics, and the Center for Vaccine Development. Division of Infectious Disease and Tropical Pediatrics. Baltimore, USA.
Emory University School of Medicine. Department of Medicine, Division of Infectious Diseases. Decatur, Georgia, USA.
Columbia University Irving Medical Center. Department of Medicine. Division of Infectious Diseases. New York, USA.
Baylor College of Medicine, Houston. Infectious Diseases Section, Department of Medicine. Texas, USA.
Fred Hutchinson Cancer Center. Vaccine and Infectious Disease Division. Seattle, Washington, USA.
Fred Hutchinson Cancer Center. Statistical Center for HIV/AIDS Research & Prevention. Washington, DC, USA.
Fred Hutchinson Cancer Center. Statistical Center for HIV/AIDS Research & Prevention. Washington, DC, USA.
University of Washington. Department of Biostatistics. Seattle, USA.
Fred Hutchinson Cancer Center. Vaccine and Infectious Disease Division. Seattle, Washington, USA / Fred Hutchinson Cancer Research Center. Bioinformatics and Epidemiology Program. Seattle, Washington, USA.
University of North Carolina at Chapel Hill School of Medicine. Department of Medicine. Division of Infectious Diseases. UNC HIV Cure Center. California, USA.
University of Rochester. Department of Medicine. Infectious Disease Division. Rochester, New York, USA.
Fred Hutchinson Cancer Center. Vaccine and Infectious Disease Division. Seattle, Washington, USA.
Biomedical Advanced Research & Development Authority. Division of Clinical Development. Washington, DC, USA.
National Institutes of Health. National Institute of Allergy and Infectious Disease. Vaccine Research Program. Division of AIDS. Bethesda, Maryland, USA.
National Institutes of Health. National Institute of Allergy and Infectious Disease. Vaccine Research Program. Division of AIDS. Bethesda, Maryland, USA.
University of Maryland. Department of Medicine. Baltimore, USA.
Fred Hutchinson Cancer Center. Vaccine and Infectious Disease Division. Seattle, Washington, USA / University of Washington. Department of Laboratory Medicine and Pathology. Seattle, Washington, USA.
Fred Hutchinson Cancer Center. Vaccine and Infectious Disease Division. Seattle, Washington, USA / University of Washington. Department of Global Health. Seattle, Washington, USA.
University of Washington, Seattle. Department of Medicine. Washington, DC, USA.
Fred Hutchinson Cancer Center. Vaccine and Infectious Disease Division. Seattle, Washington, USA / Fred Hutchinson Cancer Center. Statistical Center for HIV/AIDS Research & Prevention. Washington, DC, USA.
Brigham and Women's Hospital. Division of Infectious Diseases, Boston, Massachusetts, USA.
Baylor College of Medicine, Houston. Infectious Diseases Section, Department of Medicine. Texas, USA / Baylor College of Medicine. Department of Molecular Virology and Microbiology. Houston, Texas, USA.
National Institutes of Health. National Institute of Allergy and Infectious Diseases. Biostatistics Research Branch. Bethesda, Maryland, USA.
University of Alabama at Birmingham. Division of Infectious Diseases, Department of Medicine. Alabama, USA.
University of the Witwatersrand. Faculty of Health Sciences. Perinatal HIV Research Unit. Johannesburg, South Africa / South African Medical Research Council. Cape Town, South Africa.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. HIV/STI Clinical Research Laboratory. Rio de Janeiro, RJ, Brazil.
University of Maryland School of Medicine. Department of Pediatrics, and the Center for Vaccine Development. Division of Infectious Disease and Tropical Pediatrics. Baltimore, USA.
Emory University School of Medicine. Department of Medicine, Division of Infectious Diseases. Decatur, Georgia, USA.
Columbia University Irving Medical Center. Department of Medicine. Division of Infectious Diseases. New York, USA.
Baylor College of Medicine, Houston. Infectious Diseases Section, Department of Medicine. Texas, USA.
Fred Hutchinson Cancer Center. Vaccine and Infectious Disease Division. Seattle, Washington, USA.
Fred Hutchinson Cancer Center. Statistical Center for HIV/AIDS Research & Prevention. Washington, DC, USA.
Fred Hutchinson Cancer Center. Statistical Center for HIV/AIDS Research & Prevention. Washington, DC, USA.
University of Washington. Department of Biostatistics. Seattle, USA.
Fred Hutchinson Cancer Center. Vaccine and Infectious Disease Division. Seattle, Washington, USA / Fred Hutchinson Cancer Research Center. Bioinformatics and Epidemiology Program. Seattle, Washington, USA.
University of North Carolina at Chapel Hill School of Medicine. Department of Medicine. Division of Infectious Diseases. UNC HIV Cure Center. California, USA.
University of Rochester. Department of Medicine. Infectious Disease Division. Rochester, New York, USA.
Fred Hutchinson Cancer Center. Vaccine and Infectious Disease Division. Seattle, Washington, USA.
Biomedical Advanced Research & Development Authority. Division of Clinical Development. Washington, DC, USA.
National Institutes of Health. National Institute of Allergy and Infectious Disease. Vaccine Research Program. Division of AIDS. Bethesda, Maryland, USA.
National Institutes of Health. National Institute of Allergy and Infectious Disease. Vaccine Research Program. Division of AIDS. Bethesda, Maryland, USA.
University of Maryland. Department of Medicine. Baltimore, USA.
Fred Hutchinson Cancer Center. Vaccine and Infectious Disease Division. Seattle, Washington, USA / University of Washington. Department of Laboratory Medicine and Pathology. Seattle, Washington, USA.
Fred Hutchinson Cancer Center. Vaccine and Infectious Disease Division. Seattle, Washington, USA / University of Washington. Department of Global Health. Seattle, Washington, USA.
Abstract
Importance: The COVID-19 pandemic has caused millions of infections and deaths and resulted in unprecedented international public health social and economic crises. As SARS-CoV-2 spread across the globe and its impact became evident, the development of safe and effective vaccines became a priority. Outlining the processes used to establish and support the conduct of the phase 3 randomized clinical trials that led to the rapid emergency use authorization and approval of several COVID-19 vaccines is of major significance for current and future pandemic response efforts. Observations: To support the rapid development of vaccines for the US population and the rest of the world, the National Institute of Allergy and Infectious Diseases established the COVID-19 Prevention Network (CoVPN) to assist in the coordination and implementation of phase 3 efficacy trials for COVID-19 vaccine candidates and monoclonal antibodies. By bringing together multiple networks, CoVPN was able to draw on existing clinical and laboratory infrastructure, community partnerships, and research expertise to quickly pivot clinical trial sites to conduct COVID-19 vaccine trials as soon as the investigational products were ready for phase 3 testing. The mission of CoVPN was to operationalize phase 3 vaccine trials using harmonized protocols, laboratory assays, and a single data and safety monitoring board to oversee the various studies. These trials, while staggered in time of initiation, overlapped in time and course of conduct and ultimately led to the successful completion of multiple studies and US Food and Drug Administration-licensed or -authorized vaccines, the first of which was available to the public less than 1 year from the discovery of the virus. Conclusions and relevance: This Special Communication describes the design, geographic distribution, and underlying principles of conduct of these efficacy trials and summarizes data from 136 382 prospectively followed-up participants, including more than 2500 with documented COVID-19. These successful efforts can be replicated for other important research initiatives and point to the importance of investments in clinical trial infrastructure integral to pandemic preparedness.
Share